GSK has completed its acquisition of RAPT Therapeutics, a South San Franciso, California-based, clinical-stage bio/pharmaceutical company, for $2.2 billion. The deal was announced in January 2026. 

The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens.     

The transaction gives GSK the global rights to the ozureprubart program, excluding Mainland China, Macau, Taiwan, and Hong Kong. GSK will also be responsible for success-based milestone and royalty payments for ozureprubart owed to RAPT’s partner, Shanghai Jeyou Pharmaceutical Co.  

The total cash consideration for the acquisition amounted to an approximate aggregate equity value of $2.2 billion. Net of cash acquired, GSK’s upfront investment was approximately $1.9 billion. 

Source: GSK